Boston Scientific's stock surged 6.32% in pre-market trading after the company reported second-quarter results that exceeded analyst expectations.

The medical device maker posted adjusted earnings per share of $0.86, beating the consensus estimate of $0.83. Revenue came in at $5.442 billion, also above the expected $5.361 billion, driven by strong cardiovascular performance and emerging market growth.

The company also provided its full-year outlook, including organic revenue growth of 5-6% and adjusted EPS guidance, though the EPS forecast was slightly below some estimates. The earnings beat, coupled with positive analyst coverage and a recently announced restructuring plan, buoyed investor sentiment.